Related Experiment Video
Updated: Aug 11, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
[Paraneoplastic hypoglycemia: The hopes of pathophysiological documentation]
A Villemain1, O Menard2, D Mandry3
1Service de pneumologie, CHR de Metz-Thionville, hôpital de Mercy, 1, allée du Château, 57530 Ars-Laquenexy, France.
Doege-Potter syndrome, a rare paraneoplastic syndrome, involves non-islet cell tumor hypoglycemia caused by solitary fibrous tumors. Surgical resection of these tumors often cures the hypoglycemia, but long-term monitoring is crucial due to recurrence risks.
Area of Science:
- Endocrinology
- Oncology
- Pathology
Background:
- Doege-Potter syndrome is a rare paraneoplastic phenomenon.
- It is characterized by non-islet cell tumor hypoglycemia.
- Hypoglycemia is secondary to solitary fibrous tumors.
Observation:
- Solitary fibrous tumors are typically asymptomatic and rare.
- Hypoglycemia occurs in less than 5% of cases.
- Associated tumors are often large with high mitotic rates.
Findings:
- The hypoglycemia is caused by increased "big" insulin-like growth factor 2 (IGF-2) produced by the tumor.
- Biological tests confirming elevated "big" IGF-2 plasma levels aid diagnosis.
- Surgical resection is the primary diagnostic and therapeutic intervention.
Implications:
- Surgical resection is often curative, resolving hypoglycemia.
- Malignant transformation and recurrence are possible, necessitating long-term patient monitoring.
- Understanding the pathophysiological mechanism is key for managing this rare paraneoplastic syndrome.
Related Concept Videos
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Hypoglycemia and Glucagon
Type I Diabetes III: Clinical Manifestations
Hypoglycemia
Hyperglycemia

